WELCOME TO The PHARMACEUTICAL REPORT
Cell & Gene Therapy Manufacturing
Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...
Allergan | December 22, 2016
US-based drugmaker Allergan has signed an agreement to acquire Acelity’s regenerative medicine unit LifeCell in a deal valued at $2.9bn.The acquisition will combine LifeCell's business, including its portfolio of dermal matrix products with Allergan's portfolio of medical aesthetics, breast implants and tissue expanders....
Pharama | November 15, 2016
Along with forensic evidence in criminal cases, this process can be applied to many situations, said study lead investigator Pieter Dorrestein, a professor in UCSD's School of Medicine and Skaggs School of Pharmacy and Pharmaceutical Sciences....
PharmiWeb Solutions | February 10, 2017
Greiner Bio-One North America, Inc. has added a new and innovative product to the already robust portfolio for cell culture that is specifically used for mass cell culture. CELLdisc™ is a new multilayer device covering a range of cell culture surfaces from 1,000 cm2 up to 1 square meter. The innovative ergonomic design of CELLdisc™ provides a versatile system for the propagation of adherent mammalian cells from research scale to industrial batches....
Denovo Biopharma | February 16, 2017
Denovo Biopharma LLC, a leading company in precision medicine announces the plan to initiate a biomarker driven global phase 3 clinical trial for its lead drug DB102 as a first line therapy for diffuse large B-cell lymphoma (DLBCL) patients this year....
VIEWS AND ANALYSIS, PHARMACY MARKET
Keep me plugged in with the best
Join thousands of your peers and receive our weekly newsletter with the latest news, industry events, customer insights, and market intelligence.
Put your news, events, company, and promotional content in front of thousands of your peers and potential customers.
Not a member yet? Not a problem, Sign Up
Sign up to contribute and publish your news, events, brand, and content with the
community for FREE